Retinal cases & brief reports · 2026
Bilateral panuveitis associated with letrozole therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Brian T, Muste Justin C, Zafar Sidra, Djulbegovic Mak B, Kim Eric D, Beca Flavius A, Dunn James P, Garg Sunir J, Deaner Jordan D
Аннотация
PURPOSE: Letrozole is a non-steroidal aromatase inhibitor commonly used for the treatment of postmenopausal estrogen receptor-positive breast cancer. We report a novel case of bilateral panuveitis associated with letrozole therapy.
METHODS: Retrospective chart review.
RESULTS: A 39-year-old female with a history of breast cancer presented with bilateral anterior chamber and vitreous inflammation, perivenular sheathing, retinal hemorrhages, and a focal area of retinal whitening in the left eye six weeks after starting letrozole therapy. Extensive infectious and systemic inflammatory work-up was negative. With letrozole cessation and corticosteroid therapy, the inflammation resolved, and the visual acuity improved to 20/20 bilaterally.
DISCUSSION AND CONCLUSION: Letrozole-associated panuveitis has not previously been reported. This case highlights the importance of detailed medication history as well as the need for interdisciplinary collaboration when managing drug-induced uveitis. Early recognition and appropriate therapy can result in favorable visual outcomes.
METHODS: Retrospective chart review.
RESULTS: A 39-year-old female with a history of breast cancer presented with bilateral anterior chamber and vitreous inflammation, perivenular sheathing, retinal hemorrhages, and a focal area of retinal whitening in the left eye six weeks after starting letrozole therapy. Extensive infectious and systemic inflammatory work-up was negative. With letrozole cessation and corticosteroid therapy, the inflammation resolved, and the visual acuity improved to 20/20 bilaterally.
DISCUSSION AND CONCLUSION: Letrozole-associated panuveitis has not previously been reported. This case highlights the importance of detailed medication history as well as the need for interdisciplinary collaboration when managing drug-induced uveitis. Early recognition and appropriate therapy can result in favorable visual outcomes.